Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Accenture Plc. ( ACN - Snapshot Report ) is using its technical know-how to its advantage, banking on which the company has been winning several major deals.
Recently, insurance company Crum & Forster selected Accenture’s Duck Creek Policy Administration software to facilitate Duck Creek’s rating and policy processing system for commercial lines, which will help them improve upon their workers’ compensation process.
This apart in a separate contract, the company also won a Biosurveillance contract Recently, the U.S. Department of Homeland Security (DHS) awarded a $3 million contract to Accenture to improve biosurveillance operations of Office of Health Affairs (OHA). This is expected to help data sharing and collaboration between Homeland Security, OHA and its partners.
To fuel growth, the company has adopted a three-tier strategy to grow the business in line with economic growth. The company has set new priorities and has started growing its core business, which includes management consulting, technology and business process outsourcing.
At the same time, Accenture is making significant investments in new business and technology that could generate growth in the future. We believe that the frequent deal wins are positive outcomes of these strategic moves. We are encouraged by the steady flow of new businesses and believe that the trend will continue.
Moreover, the company is also growing inorganically and gaining access to new technologies through meaningful acquisitions. However, increasing competition from IBM Corp. ( IBM - Analyst Report ) and a tepid spending environment coupled with Accenture’s broad European exposure (roughly 40.0%) may temper its growth prospects to some extent.
Currently, Accenture has a Zacks #2 Rank (short-term Buy rating), which has been driven by upward revisions to analyst estimates.
Read the full Snapshot Report on ACN
Read the full Analyst Report on IBM